Table 2 Association between SARS-CoV-2 vaccination or infection and outcome events using self-controlled case series analysis, adjusted for calendar month between 1 February 2021 and 28 February 2022.

From: Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series study

 

Thrombocytopenia

Venous thromboembolism

Event

Patient-years

IRR (95% CI)

Event

Patient-years

IRR (95% CI)

BNT162b2

(N = 2059)

  

(N = 2500)

  

 Control period

1794

1918.35

1.00

2177

2321.86

1.00

1st dose

 Day 1–21

103

121.21

0.83 (0.68 to 1.02)

153

147.43

0.93 (0.78 to 1.10)

Subinterval

 Day 1–7

36

42.13

0.83 (0.60 to 1.16)

38

51.11

0.67 (0.48 to 0.92)

 Day 8–14

41

42.03

0.95 (0.70 to 1.30)

59

51.01

1.04 (0.80 to 1.35)

 Day 15–21

26

42.03

0.69 (0.47 to 1.02)

56

45.31

1.11 (0.85 to 1.45)

2nd dose

 Day 1–21

117

120.39

0.96 (0.79 to 1.16)

126

141.50

0.80 (0.66 to 0.96)

Subinterval

 Day 1–7

35

40.15

0.86 (0.61 to 1.21)

41

47.22

0.78 (0.57 to 1.06)

 Day 8–14

40

40.14

0.98 (0.71 to 1.35)

38

47.18

0.72 (0.52 to 1.00)

 Day 15–21

42

40.10

1.03 (0.75 to 1.40)

47

47.10

0.90 (0.67 to 1.20)

CoronaVac

(N = 985)

  

(N = 1274)

  

 Control period

867

829.86

 

1072

1076.63

1.00

1st dose

 Day 1–21

48

54.73

0.78 (0.57 to 1.08)

100

70.61

0.99 (0.79 to 1.25)

Subinterval

 Day 1–7

13

19.01

0.61 (0.35 to 1.08)

26

24.51

0.77 (0.51 to 1.15)

 Day 8–14

20

19.01

0.94 (0.59 to 1.49)

33

24.49

0.94 (0.65 to 1.35)

 Day 15–21

15

16.70

0.79 (0.47 to 1.35)

41

21.62

1.28 (0.92 to 1.77)

2nd dose

 Day 1–21

57

54.16

0.92 (0.68 to 1.23)

85

141.50

0.79 (0.62 to 1.00)

Subinterval

 Day 1–7

11

18.05

0.53 (0.29 to 0.98)

23

22.83

0.65 (0.43 to 1.00)

 Day 8–14

25

18.05

1.21 (0.80 to 1.84)

28

22.83

0.77 (0.53 to 1.14)

 Day 15–21

21

18.05

1.01 (0.65 to 1.59)

34

22.81

0.93 (0.65 to 1.32)

ChAdOx1

(N = 130)

  

(N = 172)

  

 Control period

111

119.43

1.00

145

153.44

1.00

1st dose

 Day 1–21

10

7.81

1.36 (0.67 to 2.78)

17

10.05

1.54 (0.88 to 2.73)

Subinterval

 Day 1–7

3

2.61

1.30 (0.40 to 4.28)

< 3

3.35

**

 Day 8–14

< 3

2.61

**

10

3.35

2.74 (1.37 to 5.49)

 Day 15–21

6

2.60

2.27 (0.95 to 5.45)

5

3.35

1.30 (0.51 to 3.27)

2nd dose

 Day 1–21

9

7.05

1.45 (0.68 to 3.10)

9

8.62

0.61 (0.30 to 1.22)

Subinterval

 Day 1–7

< 3

2.36

**

< 3

2.87

**

 Day 8–14

3

2.36

1.50 (0.45 to 4.96)

3

2.87

0.60 (0.19 to 1.92)

 Day 15–21

4

2.34

1.75 (0.61 to 5.00)

4

2.87

0.82 (0.30 to 2.25)

SARS-CoV-2 infection

(N = 1236)

  

(N = 4193)

  

 Control period

496

1211.13

1.00

964

4101.50

1.00

 Day 1–21

381

68.42

15.52 (13.38 to 18.00)

1929

238.77

29.84 (27.45 to 32.44)

Subinterval

 Day 1–7

317

23.34

38.09 (32.64 to 44.46)

1436

80.11

64.99 (59.60 to 70.89)

 Day 8–14

32

22.80

3.87 (2.69 to 5.57)

307

79.57

13.99 (12.26 to 15.97)

 Day 15–21

32

22.28

3.91 (2.72 to 5.63)

186

79.09

8.57 (7.30 to 10.06)

  1. Control period include days from 1 February 2021 to 28 February 2022 outside of the risk period (1–21 days post exposure), pre-risk period (− 14 to − 1 day before exposure), and day of exposure (day 0).
  2. CI confidence interval, IRR incidence rate ratio.
  3. **Value not computed for event count less than 3.
Back to article page